Quarterly report [Sections 13 or 15(d)]

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Income Statement [Abstract]    
Revenue $ 0 $ 0
Operating expenses:    
Research and development costs 95,157 96,016
General and administrative 753,148 1,172,871
Total operating expenses 848,305 1,268,887
Loss from operations (848,305) (1,268,887)
Other income (expenses):    
Interest income 217,793 547,432
Change in fair value of warrant liabilities 243,000 2,084,000
Change in fair value of derivative liability 0 1,204,000
Change in fair value of convertible note receivable - Femasys 912,000 245,000
Change in fair value of warrant asset - Femasys (1,215,000) (1,510,000)
Change in fair value of investment - TNF (2,839,000) 966,950
Change in fair value of warrants - TNF (4,832,000) (242,684)
Gain on legal settlement - re-fair value of warrants 106,000 0
Gain on related party investment - TNF 0 21,395,734
Unrealized loss on marketable securities (104,463) 0
Other expense (121) (190)
Total other income (loss), net (7,511,791) 24,690,242
Net income (loss) (8,360,096) 23,421,355
Preferred stock dividends 0 (685,801)
Preferred stock accretion 0 (2,148,047)
Net income (loss) attributable to common stockholders $ (8,360,096) $ 20,587,507
Basic income (loss) per share attributable to common stockholders $ (1.23) $ 1.90
Diluted income (loss) per share attributable to common stockholders $ (1.23) $ 1.90
Weighted average shares outstanding basic 6,795,779 7,866,387
Weighted average shares outstanding diluted 6,795,779 7,866,387